Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betaine is a naturally occurring choline derivative and methyl group donor used primarily to treat homocystinuria, an inherited disorder that results in elevated levels of homocysteine in the blood and urine. By donating a methyl group, betaine facilitates the remethylation of homocysteine to methionine, thereby lowering plasma homocysteine concentrations. This mechanism helps prevent complications such as blood clots, abnormal bone structure, osteoporosis, lens dislocation in the eye, and developmental delays associated with high homocysteine levels. Betaine is not a cure for homocystinuria but serves as an adjunct therapy to manage symptoms and reduce risk of serious complications. It is available as an oral powder or tablet for solution[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betaine.